Below are the most recent publications written about "Hypersensitivity, Delayed" by people in Profiles.
-
Kocer N, Mondel PK, Yamac E, Kavak A, Kizilkilic O, Islak C. Is there an association between flow diverter fish mouthing and delayed-type hypersensitivity to metals?-a case-control study. Neuroradiology. 2017 Nov; 59(11):1171-1178.
-
Gómez D, Diehl MC, Crosby EJ, Weinkopff T, Debes GF. Effector T Cell Egress via Afferent Lymph Modulates Local Tissue Inflammation. J Immunol. 2015 Oct 15; 195(8):3531-6.
-
Seidler DG, Mohamed NA, Bocian C, Stadtmann A, Hermann S, Schäfers K, Schäfers M, Iozzo RV, Zarbock A, Götte M. The role for decorin in delayed-type hypersensitivity. J Immunol. 2011 Dec 1; 187(11):6108-19.
-
Mahipal A, Terai M, Berd D, Chervoneva I, Patel K, Mastrangelo MJ, Sato T. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol Immunother. 2011 Jul; 60(7):1039-45.
-
Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Solt S, Onners B, Tartakovsky I, Choi M, Sharma R, Illei PB, Hruban RH, Abrams RA, Le D, Jaffee E, Laheru D. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011 Feb; 253(2):328-35.
-
Dillman RO, Selvan SR, Schiltz PM, McClay EF, Barth NM, DePriest C, de Leon C, Mayorga C, Cornforth AN, Allen K. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report. Cancer Biother Radiopharm. 2009 Jun; 24(3):311-9.
-
Dillman RO, Beutel L, Nayak S, Depriest C, Selvan S, Schiltz P. Cancer vaccine potency: is there a dose/response relationship for patient-specific vaccines and clinical outcomes? Cancer Biother Radiopharm. 2005 Aug; 20(4):373-8.
-
Dillman R, Selvan S, Schiltz P, Peterson C, Allen K, Depriest C, McClay E, Barth N, Sheehy P, de Leon C, Beutel L. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis. Cancer Biother Radiopharm. 2004 Oct; 19(5):658-65.
-
Dillman R, Barth N, Selvan S, Beutel L, de Leon C, DePriest C, Peterson C, Nayak S. Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas. Cancer Biother Radiopharm. 2004 Oct; 19(5):581-8.
-
Berd D, Sato T, Maguire HC, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol. 2004 Feb 1; 22(3):403-15.